Lupin lines up 50 generic products for Australia as patent expiries loom
This article was originally published in Scrip
Lupin is scaling up its operations in the Australian market, beefing up its sales force and product portfolio there ahead of an anticipated flurry of patent expiries for leading prescription products.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.